JGH Open is a prominent open-access journal dedicated to advancing knowledge in the fields of Gastroenterology and Hepatology, published by WILEY. Since its inception in 2017, the journal has served as a crucial platform for researchers, professionals, and students to disseminate innovative research findings and clinical insights. With an impact factor and Scopus rankings reflecting its steady growth—ranking in the 3rd quartile for both Gastroenterology (Q3) and Hepatology (Q3)—JGH Open is positioned within the competitive landscape of medicine. Its commitment to open access enhances the visibility and accessibility of high-quality research, ensuring that significant advancements in understanding diseases of the gastrointestinal tract and liver reach a broad audience. With a focus on collaboration and dissemination of knowledge, JGH Open aims to contribute to the global discourse and improve outcomes in gastrointestinal health.

Korean Journal of Gastroenterology (ISSN: 1598-9992, E-ISSN: 2233-6869), published by the Korean Society of Gastroenterology, has been a premier outlet for research and advancements in the field of gastroenterology since its inception in 1968. This open-access journal, based in South Korea, fosters a global dialogue on gastrointestinal health, embracing contributions from a diverse array of disciplines within medicine. It is currently ranked in the Q4 quartile for miscellaneous medicine and holds a Scopus rank of #323 out of 636 in general medicine, reflecting its commitment to publishing impactful research despite its relatively recent establishment in high-impact metrics. With a continuous publication timeline extending through to 2024, the journal aims to enhance understanding of gastrointestinal disorders and promote innovative treatments, making it an essential resource for researchers, clinicians, and students alike who seek to stay abreast of the latest developments and clinical applications in gastroenterology.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Annals of Hepatology is an esteemed open-access journal dedicated to the dynamic field of liver research and hepatology. Published by Elsevier España since 2002, this journal has established itself as a pivotal resource for researchers and clinicians alike, boasting a remarkable impact in the medical community with its 2023 rankings placing it in the Q2 quartile for Hepatology and Q1 quartile in Medicine (Miscellaneous). With an impressive Scopus rank of #20 out of 82 in the field of Hepatology and a notable 76th percentile standing, the journal is committed to disseminating high-quality, peer-reviewed articles that advance the understanding of liver diseases and their management. The editorial scope encompasses a broad range of topics, including liver pathology, therapeutic interventions, and public health implications related to hepatic disorders. Researchers, healthcare professionals, and students interested in the latest advancements in hepatology will find Annals of Hepatology an invaluable platform for sharing and accessing knowledge, with the convenience of open access enhancing global visibility and collaboration in this critical field of medicine.

Clinics in Liver Disease is an esteemed peer-reviewed journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of hepatology. Established in 1997 and covering a broad range of topics within liver disease research, this journal serves as a vital resource for researchers, clinicians, and students engaged in the study of liver health and diseases. With a commendable impact factor placing it within the Q2 category in Hepatology and ranking #32 out of 82 in the Scopus classifications, it consistently disseminates high-quality research and clinical insights. The journal’s commitment to promoting understanding and management of liver diseases is reflected in its rigorous editorial standards and comprehensive review processes. Although not an open-access publication, Clinics in Liver Disease offers subscription options that ensure accessibility to up-to-date research and reviews critical for both academic and clinical success.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, a pivotal Open Access journal published by ARAN EDICIONES, S A, has been at the forefront of advancing the field of gastroenterology since its inception in 1990. With a robust commitment to disseminating high-quality research, the journal provides a platform for researchers, clinicians, and students to share innovative findings and insights concerning digestive diseases. The journal is characterized by its Q3 ranking in both Gastroenterology and Miscellaneous Medicine categories, indicative of its significant contributions to these fields, and is positioned within the 36th percentile of Scopus rankings for medicine related to gastroenterology. Based in Spain, REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS has embraced the Open Access model since 2004, ensuring that its articles are readily available to a global audience without financial barriers. The journal not only supports academic discourse but also plays a crucial role in improving clinical practices and health outcomes related to digestive health.

SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.